Axsome Therapeutics Reports 57.4% Revenue Growth to $191.2 Million in Q1 2026

Axsome Therapeutics, Inc. reported significant financial results for the first quarter of 2026, with total revenues reaching $191.2 million, a 57.4% increase from $121.5 million in the same period of 2025. The growth was primarily driven by increased product sales, particularly from AUVELITY, which generated $152.7 million in net sales compared to $96.2 million a year earlier. SUNOSI also contributed with net sales of $32.6 million, up from $24.1 million, while SYMBRAVO, launched in June 2025, added $4.1 million in sales. Despite the revenue growth, the company reported a net loss of $64.5 million, slightly higher than the $59.4 million loss recorded in the prior year, attributed to increased selling, general, and administrative expenses.

The company’s operating expenses for the quarter totaled $254.6 million, up from $178.4 million in the previous year. This increase was largely due to higher costs associated with research and development, which rose to $52.7 million from $44.8 million, and selling, general, and administrative expenses, which surged to $185.0 million from $120.8 million. The rise in expenses reflects Axsome's ongoing efforts to expand its commercial infrastructure and support the launch of its products, particularly AUVELITY for the treatment of agitation associated with Alzheimer’s disease.

In terms of strategic developments, Axsome has been active in expanding its product portfolio through acquisitions. In the first quarter of 2026, the company acquired global rights to AXS-20, a selective PDE10A inhibitor, from Takeda Pharmaceutical Company for $10.4 million. This acquisition is part of Axsome's strategy to enhance its pipeline targeting central nervous system conditions. Additionally, the company has entered into a licensing agreement with Pharmanovia to market SUNOSI in Europe and certain countries in the Middle East and North Africa, which is expected to further bolster its revenue streams.

As of March 31, 2026, Axsome reported total assets of $713.6 million, an increase from $689.8 million at the end of 2025. The company had cash and cash equivalents of $305.1 million, down from $322.9 million, and accounts receivable increased to $251.1 million from $224.5 million. The company’s employee headcount stood at 1,220 as of April 27, 2026, reflecting its growth in operational capacity. Looking ahead, Axsome anticipates continued investment in its product candidates and commercialization efforts, with expectations of increased expenses as it seeks to achieve profitability. The company believes its existing cash will be sufficient to fund operations for at least the next twelve months, although it may seek additional financing to support its growth initiatives.